Troglitazone is a novel antidiabetic agent of the thiazolidinedione family that can be used to improve insulin resistance. Its pharmacological agonist actions are mediated by peroxisome proliferator–activated receptor-γ (PPAR-γ). Peroxisome proliferator–activated receptor-γ agonists, 15-deoxy-Δ12,14-prostaglandin J2, and troglitazone have been shown to inhibit the secretion of inflammatory cytokines from monocytes, suggesting that there may be a therapeutic application of PPAR-γ agonists for chronic inflammatory diseases, such as rheumatoid arthritis.1,2 We report a case in which the patient's rheumatoid arthritis deteriorated after administration of troglitazone (Noscal; Sankyo Co Ltd, Tokyo, Japan).
Sakurai A, Hashizume K. Deterioration of Rheumatoid Arthritis With Troglitazone: A Rare and Unexpected Adverse Effect. Arch Intern Med. 2000;160(1):118–119. doi: